Clinical Trials Browser

Phase 2 × orelabrutinib × Other hematologic neoplasm × Clear all

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05322733 2022-04-19

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell